About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Polr2a+
wild type
MGI:2435433
Summary 13 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
ht1
 		Polr2atm2Cdn/Polr2a+ involves: 129S1/Sv * 129X1/SvJ * C57BL/6J MGI:3652411
cn2
 		Mapk14tm2Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+ 		involves: 129 * C57BL/6 * CD-1 * SJL MGI:3716853
cn3
 		Braftm1Mmcm/Braf+
Polr2atm1(cre/ERT2)Bbd/Polr2a+ 		involves: 129P2/OlaHsd * C57BL/6 * SJL MGI:3712024
cn4
 		Polr2atm1(cre/ERT2)Bbd/Polr2a+
Rnf2tm1Mvi/Rnf2tm1Mvi 		involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/10 * SJL MGI:3772193
cn5
 		Krastm1Bbd/Kras+
Mapk14tm2Nbr/Mapk14+
Polr2atm1(cre/ERT2)Bbd/Polr2a+ 		involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL MGI:3716857
cn6
 		Mapk14tm1Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+ 		involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL MGI:3716854
cn7
 		Krastm1Bbd/Kras+
Mapk14tm1Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+ 		involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL MGI:3716855
cn8
 		E4f1tm1Pisc/E4f1tm1.1Llca
Polr2atm1(cre/ERT2)Bbd/Polr2a+ 		involves: 129S4/SvJae * C57BL/6 * SJL MGI:4867861
cn9
 		Cdkn2atm1Rdp/Cdkn2atm1Rdp
E4f1tm1Pisc/E4f1tm1.1Llca
Polr2atm1(cre/ERT2)Bbd/Polr2a+ 		involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL MGI:4867863
cn10
 		Cdc20tm1.1Mama/Cdc20tm1.2Mama
Polr2atm1(cre/ERT2)Bbd/Polr2a+ 		involves: 129/Sv * BALB/cJ * C57BL/6 * CD-1 * SJL MGI:4887575
cn11
 		Ebf1tm1.1Rug/Ebf1tm1.1Rug
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Tg(BCL2)#Wehi/0 		involves: C57BL/6 * C57BL/6JWehi * SJL * SJL/JWehi MGI:5316372
cn12
 		Ebf1tm1.1Rug/Ebf1tm1.1Rug
Polr2atm1(cre/ERT2)Bbd/Polr2a+ 		involves: C57BL/6 * SJL MGI:5316370
cn13
 		Mastltm1.1Mama/Mastltm1.1Mama
Polr2atm1(cre/ERT2)Bbd/Polr2a+ 		Not Specified MGI:5556128


Genotype
MGI:3652411
ht1
Allelic
Composition		 Polr2atm2Cdn/Polr2a+
Genetic
Background		 involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Polr2atm2Cdn mutation (0 available); any Polr2a mutation (92 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
growth/size/body
decreased fetal size ( J:53757 )
• reduced body weight at E17.5 - E18.5 compared to wild-type mice, but mice are heavier than homozygotes




Genotype
MGI:3716853
cn2
Allelic
Composition		 Mapk14tm2Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Genetic
Background		 involves: 129 * C57BL/6 * CD-1 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mapk14tm2Nbr mutation (2 available); any Mapk14 mutation (43 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
respiratory system
abnormal lung morphology ( J:122397 )
• 2 weeks after 5-hydroxytamoxifen treatment, lungs show increased cellularity
abnormal lung epithelium morphology ( J:122397 )
• lungs show multicellular septa and reduction of the alveolar lumen as early as 2 weeks after 5-hydroxytamoxifen treatment, and is marked after 8 weeks, extending to 60% of the lungs
abnormal pulmonary alveolus epithelial cell morphology ( J:122397 )
• after 5-hydroxytamoxifen treatment, there is an increase in alveolar type II cells compared to controls
• when cultured, isolated progenitor and stem cells (SP-C+, CC-10+ cells) when put under differentiation conditions do not have the capacity to form single positive cells; overexpression of C/EBP alpha in these cells restores the capacity to form SP-C+ cells

cellular
increased cell proliferation ( J:122397 )
• 8 weeks after 5-hydroxytamoxifen treatment, lungs display hyperproliferation (~5-fold increased proliferation) compared to wild-type or heterozygous lungs




Genotype
MGI:3712024
cn3
Allelic
Composition		 Braftm1Mmcm/Braf+
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Genetic
Background		 involves: 129P2/OlaHsd * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Mmcm mutation (4 available); any Braf mutation (61 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
increased lung adenoma incidence ( J:121715 )
• with induction of Cre expression from the transgene, multiple adenomatous tumors form in mouse lungs

respiratory system
increased lung adenoma incidence ( J:121715 )
• with induction of Cre expression from the transgene, multiple adenomatous tumors form in mouse lungs




Genotype
MGI:3772193
cn4
Allelic
Composition		 Polr2atm1(cre/ERT2)Bbd/Polr2a+
Rnf2tm1Mvi/Rnf2tm1Mvi
Genetic
Background		 involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/10 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
Rnf2tm1Mvi mutation (1 available); any Rnf2 mutation (34 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
abnormal bone marrow cell morphology/development ( J:130397 )
• when cells are exposed to tamoxifen ex vivo, the progenitor compartment is increased compared to unexposed cells
abnormal common myeloid progenitor cell morphology ( J:130397 )
• when cells are exposed to tamoxifen ex vivo, the number of myeloid colony forming units is increased compared to unexposed cells
• when cells are exposed to tamoxifen ex vivo, the proliferation of myeloid precursor cells is increased compared to unexposed cells
• however, myeloid cell apoptosis rates and differentiation are normal
decreased B cell number ( J:130397 )
• when cells are exposed to tamoxifen ex vivo, fewer pre-B cells are present compared to unexposed cells

immune system
decreased B cell number ( J:130397 )
• when cells are exposed to tamoxifen ex vivo, fewer pre-B cells are present compared to unexposed cells




Genotype
MGI:3716857
cn5
Allelic
Composition		 Krastm1Bbd/Kras+
Mapk14tm2Nbr/Mapk14+
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Genetic
Background		 involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (88 available)
Mapk14tm2Nbr mutation (2 available); any Mapk14 mutation (43 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:122397 )
• mice live up to 40 weeks

neoplasm
increased hemolymphoid system tumor incidence ( J:122397 )
• by 24 weeks, mice develop tumors in the thymus
increased lung tumor incidence ( J:122397 )
• by 24 weeks, mice develop tumors in lungs
increased lung adenoma incidence ( J:122397 )
• at 4 weeks after 5-hydroxytamoxifen treatment, a few small adenomas are observed in some animals

respiratory system
increased lung tumor incidence ( J:122397 )
• by 24 weeks, mice develop tumors in lungs
increased lung adenoma incidence ( J:122397 )
• at 4 weeks after 5-hydroxytamoxifen treatment, a few small adenomas are observed in some animals




Genotype
MGI:3716854
cn6
Allelic
Composition		 Mapk14tm1Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Genetic
Background		 involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mapk14tm1Nbr mutation (0 available); any Mapk14 mutation (43 available)
Mapk14tm2Nbr mutation (2 available); any Mapk14 mutation (43 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:122397 )
• mice die before week 32 due to increased lung cancer progression

respiratory system
enlarged lung ( J:122397 )
• 20 weeks after treatment, lungs are increased in size
increased lung tumor incidence ( J:122397 )
• 2 weeks after 5-hydroxytamoxifen treatment, small tumors are found in the lungs
• 20 weeks after treatment, lungs are oversized with 2-3 times as many tumors, many often >2mm in diameter, while lungs of Kras, Mapk14 heterozygotes have normal lungs with fewer, smaller tumors; tumors in Mapk14 homozygotes are more poorly differentiated and have higher mitotic indices
• at 26 weeks, total tumor number is slightly higher than in controls with much higher numbers of tumors larger than 2 mm in diameter and a higher ratio of lung mass to total mass
increased lung adenoma incidence ( J:122397 )
• tumors are detected 2 weeks after 5-hydroxytamoxifen treatment and after 4 weeks, clear signs of adenomas are present in most lungs compared to only a few small adenomas in lungs of treated Kras, Mapk14tm2Nbr/+ control mice
increased lung adenocarcinoma incidence ( J:122397 )
• adenocarcinomas are detected at 15 weeks but not in controls
abnormal lung development ( J:122397 )
• lung differentiation is abnormal with increased SP-C-positive cells

neoplasm
abnormal tumor incidence ( J:122397 )
• mice also have tumors in the thymus and organs such as kidney and liver by 24 weeks after treatment whereas controls only have tumors in lungs and thymus
increased lung tumor incidence ( J:122397 )
• 2 weeks after 5-hydroxytamoxifen treatment, small tumors are found in the lungs
• 20 weeks after treatment, lungs are oversized with 2-3 times as many tumors, many often >2mm in diameter, while lungs of Kras, Mapk14 heterozygotes have normal lungs with fewer, smaller tumors; tumors in Mapk14 homozygotes are more poorly differentiated and have higher mitotic indices
• at 26 weeks, total tumor number is slightly higher than in controls with much higher numbers of tumors larger than 2 mm in diameter and a higher ratio of lung mass to total mass
increased lung adenoma incidence ( J:122397 )
• tumors are detected 2 weeks after 5-hydroxytamoxifen treatment and after 4 weeks, clear signs of adenomas are present in most lungs compared to only a few small adenomas in lungs of treated Kras, Mapk14tm2Nbr/+ control mice
increased lung adenocarcinoma incidence ( J:122397 )
• adenocarcinomas are detected at 15 weeks but not in controls

growth/size/body
enlarged lung ( J:122397 )
• 20 weeks after treatment, lungs are increased in size




Genotype
MGI:3716855
cn7
Allelic
Composition		 Krastm1Bbd/Kras+
Mapk14tm1Nbr/Mapk14tm2Nbr
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Genetic
Background		 involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1Bbd mutation (2 available); any Kras mutation (88 available)
Mapk14tm1Nbr mutation (0 available); any Mapk14 mutation (43 available)
Mapk14tm2Nbr mutation (2 available); any Mapk14 mutation (43 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:122397 )
• mice die before week 32 due to increased lung cancer progression

respiratory system
enlarged lung ( J:122397 )
• 20 weeks after treatment, lungs are increased in size
increased lung tumor incidence ( J:122397 )
• 2 weeks after 5-hydroxytamoxifen treatment, small tumors are found in the lungs
• 20 weeks after treatment, lungs are oversized with 2-3 times as many tumors, many often >2mm in diameter, while lungs of Kras, Mapk14 heterozygotes have normal lungs with fewer, smaller tumors; tumors in Mapk14 homozygotes are more poorly differentiated and have higher mitotic indices
• at 26 weeks, total tumor number is slightly higher than in controls with much higher numbers of tumors larger than 2 mm in diameter and a higher ratio of lung mass to total mass
increased lung adenoma incidence ( J:122397 )
• tumors are detected 2 weeks after 5-hydroxytamoxifen treatment and after 4 weeks, clear signs of adenomas are present in most lungs compared to only a few small adenomas in lungs of treated Kras, Mapk14tm2Nbr/+ control mice
increased lung adenocarcinoma incidence ( J:122397 )
• adenocarcinomas are detected at 15 weeks but not in controls
abnormal lung development ( J:122397 )
• lung differentiation is abnormal with increased SP-C-positive cells

neoplasm
abnormal tumor incidence ( J:122397 )
• mice also have tumors in the thymus and organs such as kidney and liver by 24 weeks after treatment whereas controls only have tumors in lungs and thymus
increased lung tumor incidence ( J:122397 )
• 2 weeks after 5-hydroxytamoxifen treatment, small tumors are found in the lungs
• 20 weeks after treatment, lungs are oversized with 2-3 times as many tumors, many often >2mm in diameter, while lungs of Kras, Mapk14 heterozygotes have normal lungs with fewer, smaller tumors; tumors in Mapk14 homozygotes are more poorly differentiated and have higher mitotic indices
• at 26 weeks, total tumor number is slightly higher than in controls with much higher numbers of tumors larger than 2 mm in diameter and a higher ratio of lung mass to total mass
increased lung adenoma incidence ( J:122397 )
• tumors are detected 2 weeks after 5-hydroxytamoxifen treatment and after 4 weeks, clear signs of adenomas are present in most lungs compared to only a few small adenomas in lungs of treated Kras, Mapk14tm2Nbr/+ control mice
increased lung adenocarcinoma incidence ( J:122397 )
• adenocarcinomas are detected at 15 weeks but not in controls

growth/size/body
enlarged lung ( J:122397 )
• 20 weeks after treatment, lungs are increased in size




Genotype
MGI:4867861
cn8
Allelic
Composition		 E4f1tm1Pisc/E4f1tm1.1Llca
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Genetic
Background		 involves: 129S4/SvJae * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
E4f1tm1.1Llca mutation (2 available); any E4f1 mutation (38 available)
E4f1tm1Pisc mutation (1 available); any E4f1 mutation (38 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
homeostasis/metabolism
impaired wound healing ( J:167157 )
• after topical application of 4-hydroxytamoxifen

integument
alopecia ( J:167157 )
• topical application of 4-hydroxytamoxifen to the unshaved tail results in complete alopecia by 6 weeks after application
abnormal hair follicle bulge morphology ( J:167157 )
• fewer hair follicle bulges are detected 4 - 6 weeks after topical application of 4-hydroxytamoxifen
• at 2 - 3 weeks after topical application of 4-hydroxytamoxifen the long term retaining cell region is expanded but by 6 weeks after application long term retaining cells appear to be lost
abnormal skin morphology ( J:167157 )
• broad disorganization of the interfollicular epithelium develops by 3 - 4 weeks after topical application of 4-hydroxytamoxifen
• hyperkeratosis is associated with loss of cellularity in the interfollicular epithelium
hyperkeratosis ( J:167157 )
• develops by 3 - 4 weeks after topical application of 4-hydroxytamoxifen
absent epidermis stratum granulosum ( J:167157 )
• after topical application of 4-hydroxytamoxifen
absent suprabasal layer ( J:167157 )
• after topical application of 4-hydroxytamoxifen
epidermal hyperplasia ( J:167157 )
• massive hyperplasia with increased cellularity in the interfollicular epithelium and the infundibulum in the first few weeks after topical application of 4-hydroxytamoxifen
• no abnormal cell death is seen in these lesions
spontaneous skin ulceration ( J:167157 )
• by 2 - 4 weeks after topical application of 4-hydroxytamoxifen, severe skin ulcerative lesions develop
abnormal skin condition ( J:167157 )
• between 1 - 2 weeks after topical application of 4-hydroxytamoxifen, back skin is ruffled and wrinkled
thick skin ( J:167157 )
• between 1 - 2 weeks after topical application of 4-hydroxytamoxifen, back skin is thickened
abnormal skin physiology ( J:167157 )
• increase in the proportion of proliferating epidermal cells in the first few weeks after topical application of 4-hydroxytamoxifen
abnormal keratinocyte physiology ( J:167157 )
• after 10 - 15 days in culture keratinocytes from 4-hydroxytamoxifen treated skin fail to develop typical holoclones (corresponding to long term clonal outgrowth of epidermal stem cells)




Genotype
MGI:4867863
cn9
Allelic
Composition		 Cdkn2atm1Rdp/Cdkn2atm1Rdp
E4f1tm1Pisc/E4f1tm1.1Llca
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Genetic
Background		 involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2atm1Rdp mutation (6 available); any Cdkn2a mutation (67 available)
E4f1tm1.1Llca mutation (2 available); any E4f1 mutation (38 available)
E4f1tm1Pisc mutation (1 available); any E4f1 mutation (38 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
integument
hyperkeratosis ( J:167157 )
• development of hyperkeratosis following 4-hydroxytamoxifen treatment is reduced and delayed compared to mutant mice wild-type for Cdkn2a
epidermal hyperplasia ( J:167157 )
• development of hyperplasia following 4-hydroxytamoxifen treatment is reduced and delayed compared to mutant mice wild-type for Cdkn2a
abnormal keratinocyte physiology ( J:167157 )
• partial restoration in long term outgrowth of 4-hydroxytamoxifen exposed keratinocytes in culture compared to mutant mice wild-type for Cdkn2a




Genotype
MGI:4887575
cn10
Allelic
Composition		 Cdc20tm1.1Mama/Cdc20tm1.2Mama
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Genetic
Background		 involves: 129/Sv * BALB/cJ * C57BL/6 * CD-1 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdc20tm1.1Mama mutation (1 available); any Cdc20 mutation (30 available)
Cdc20tm1.2Mama mutation (0 available); any Cdc20 mutation (30 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:167609 )
• after 8 to 10 days on a tamoxifen diet
• however, survival is increased when older mice (1 year old) are treated with tamoxifen

cellular
abnormal mitosis ( J:167609 )
• tamoxifen-treated mice exhibit widespread metaphase arrest in proliferative areas of the intestine and testis unlike in control mice
• topical treatment results in metaphase figures in the basal layer and in the hair follicle cells in depilated mice compared to in similarly treated control mice
decreased cell proliferation ( J:167609 )
• tamoxifen-treated mice exhibit reduced proliferation in the testis and spleen compared with control mice

neoplasm
decreased tumor growth/size ( J:167609 )
• in a two-stage carcinogenesis protocol, tamoxifen-treated mice exhibit tumor arrest unlike similarly treated control mice
tumor regression ( J:167609 )
• in tamoxifen-treated mice

integument
delayed hair regrowth ( J:167609 )
• following topical application of tamoxifen, depilated mice exhibit impaired hair regeneration compared with similarly treated control mice
abnormal epidermis stratum basale morphology ( J:167609 )
• topical treatment results in metaphase figures in the basal layer compared to in similarly treated control mice

digestive/alimentary system
abnormal intestinal epithelium morphology ( J:167609 )
• tamoxifen-treated mice exhibit loss of intestinal epithelium unlike in control mice

growth/size/body
weight loss ( J:167609 )
• in tamoxifen-treated mice




Genotype
MGI:5316372
cn11
Allelic
Composition		 Ebf1tm1.1Rug/Ebf1tm1.1Rug
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Tg(BCL2)#Wehi/0
Genetic
Background		 involves: C57BL/6 * C57BL/6JWehi * SJL * SJL/JWehi
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ebf1tm1.1Rug mutation (0 available); any Ebf1 mutation (75 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
Tg(BCL2)#Wehi mutation (0 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
decreased immature B cell number ( J:182210 )
• fewer CD25-kappa+ immature B cells in tamoxifen-treated mice
decreased pre-B cell number ( J:182210 )
• fewer CD25+kappa- pre-B cells in tamoxifen-treated mice

hematopoietic system
decreased immature B cell number ( J:182210 )
• fewer CD25-kappa+ immature B cells in tamoxifen-treated mice
decreased pre-B cell number ( J:182210 )
• fewer CD25+kappa- pre-B cells in tamoxifen-treated mice




Genotype
MGI:5316370
cn12
Allelic
Composition		 Ebf1tm1.1Rug/Ebf1tm1.1Rug
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Genetic
Background		 involves: C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ebf1tm1.1Rug mutation (0 available); any Ebf1 mutation (75 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
immune system phenotype ( J:182210 )
N
• tamoxifen-treated mice exhibit normal somatic hypermutation
increased B cell apoptosis ( J:182210 )
• tamoxifen-treated pro-B cells exhibit reduced survival compared with wild-type mice that cannot be rescued by expression of Bcl2 or Foxo1 or transformation with A-MuLV
• stimulated B cells from tamoxifen-treated mice exhibit reduced survival compared with control cells
• however, expression of Myb or BAFF rescues B cell survival and expression of Bcl2l1 partially rescues B survival
decreased B cell proliferation ( J:182210 )
• with cell cycle defects in tamoxifen-treated mice
• of B cells from tamoxifen-treated mice stimulated with LPS, CpG or anti-IgM
• tamoxifen-treated mice exhibit impaired germinal center formation and germinal center B cell proliferation compared with control mice
• however, B cell proliferation is rescued by transformation with A-MuLV
decreased immature B cell number ( J:182210 )
• in tamoxifen-treated mice
decreased transitional stage B cell number ( J:182210 )
• in tamoxifen-treated mice
arrested B cell differentiation ( J:182210 )
• of pre-B cells from tamoxifen-treated mice in vitro
decreased germinal center B cell number ( J:182210 )
• in tamoxifen-treated mice, less severe 12 days after immunization
decreased marginal zone B cell number ( J:182210 )
• in tamoxifen-treated mice
decreased pre-B cell number ( J:182210 )
• reduced frequency of B220intCD43- pre-B cells in tamoxifen-treated mice
increased B cell number ( J:182210 )
• increased number of recirculating B220hiCD43- B cells in tamoxifen-treated mice
decreased spleen germinal center number ( J:182210 )
• in immunized tamoxifen-treated mice
abnormal germinal center B cell physiology ( J:182210 )
• tamoxifen-treated mice exhibit impaired germinal center formation and germinal center B cell proliferation compared with control mice
decreased IgG1 level ( J:182210 )
• by a factor of 5 in tamoxifen treated mice
decreased IgG3 level ( J:182210 )
• by a factor of 3 in tamoxifen treated mice

cellular
increased B cell apoptosis ( J:182210 )
• tamoxifen-treated pro-B cells exhibit reduced survival compared with wild-type mice that cannot be rescued by expression of Bcl2 or Foxo1 or transformation with A-MuLV
• stimulated B cells from tamoxifen-treated mice exhibit reduced survival compared with control cells
• however, expression of Myb or BAFF rescues B cell survival and expression of Bcl2l1 partially rescues B survival
decreased B cell proliferation ( J:182210 )
• with cell cycle defects in tamoxifen-treated mice
• of B cells from tamoxifen-treated mice stimulated with LPS, CpG or anti-IgM
• tamoxifen-treated mice exhibit impaired germinal center formation and germinal center B cell proliferation compared with control mice
• however, B cell proliferation is rescued by transformation with A-MuLV

hematopoietic system
increased B cell apoptosis ( J:182210 )
• tamoxifen-treated pro-B cells exhibit reduced survival compared with wild-type mice that cannot be rescued by expression of Bcl2 or Foxo1 or transformation with A-MuLV
• stimulated B cells from tamoxifen-treated mice exhibit reduced survival compared with control cells
• however, expression of Myb or BAFF rescues B cell survival and expression of Bcl2l1 partially rescues B survival
decreased B cell proliferation ( J:182210 )
• with cell cycle defects in tamoxifen-treated mice
• of B cells from tamoxifen-treated mice stimulated with LPS, CpG or anti-IgM
• tamoxifen-treated mice exhibit impaired germinal center formation and germinal center B cell proliferation compared with control mice
• however, B cell proliferation is rescued by transformation with A-MuLV
decreased immature B cell number ( J:182210 )
• in tamoxifen-treated mice
decreased transitional stage B cell number ( J:182210 )
• in tamoxifen-treated mice
arrested B cell differentiation ( J:182210 )
• of pre-B cells from tamoxifen-treated mice in vitro
decreased germinal center B cell number ( J:182210 )
• in tamoxifen-treated mice, less severe 12 days after immunization
decreased marginal zone B cell number ( J:182210 )
• in tamoxifen-treated mice
decreased pre-B cell number ( J:182210 )
• reduced frequency of B220intCD43- pre-B cells in tamoxifen-treated mice
increased B cell number ( J:182210 )
• increased number of recirculating B220hiCD43- B cells in tamoxifen-treated mice
decreased spleen germinal center number ( J:182210 )
• in immunized tamoxifen-treated mice
abnormal germinal center B cell physiology ( J:182210 )
• tamoxifen-treated mice exhibit impaired germinal center formation and germinal center B cell proliferation compared with control mice
decreased IgG1 level ( J:182210 )
• by a factor of 5 in tamoxifen treated mice
decreased IgG3 level ( J:182210 )
• by a factor of 3 in tamoxifen treated mice




Genotype
MGI:5556128
cn13
Allelic
Composition		 Mastltm1.1Mama/Mastltm1.1Mama
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Genetic
Background		 Not Specified
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mastltm1.1Mama mutation (0 available); any Mastl mutation (36 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
cellular
abnormal mitosis ( J:201971 )
• following treatment with tamoxifen at E12.5, at E14.5 an increase in mitotic figures is seen in the neuroepithelium
• mitotic figures display an accumulation of prometaphases/metaphases

embryo
abnormal embryonic neuroepithelium morphology ( J:201971 )
• following treatment with tamoxifen at E12.5, at E14.5 an increase in mitotic figures is seen in the neuroepithelium

nervous system
abnormal embryonic neuroepithelium morphology ( J:201971 )
• following treatment with tamoxifen at E12.5, at E14.5 an increase in mitotic figures is seen in the neuroepithelium




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
03/25/2025
MGI 6.24 		The Jackson Laboratory